Drug Database · Clinicians

Methimazole

Also known as: thiamazole (international nonproprietary name)

Brands (12) Tapdin, Methazol, Methimed…Show all

Thyroid Hormone Synthesis Inhibitor (Thyroid Hormone Synthesis Inhibitors) US FDA class
Antithyroid (sulfur-containing imidazole derivative); Antithyroid (thioamide); and others PH FDA category

Rx · Prescription drug20 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 06bb4bcc-5e47-48b6-a76c-648f846704e8, version date August 20, 2026 (Methimazole · AiPing Pharmaceutical, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Methimazole tablets are indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Methimazole tablets are indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option. To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.

Contraindications

CONTRAINDICATIONS Methimazole tablets are contraindicated in the presence of hypersensitivity to the drug or any of the other product components.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Methimazole tablets are administered orally. The total daily dosage is usually given in 3 divided doses at approximately 8-hour intervals. Adult - The initial daily dosage is 15 mg for mild hyperthyroidism, 30 to 40 mg for moderately severe hyperthyroidism, and 60 mg for severe hyperthyroidism, divided into 3 doses at 8-hour intervals. The maintenance dosage is 5 to 15 mg daily. Pediatric - Initially, the daily dosage is 0.4 mg/kg of body weight divided into 3 doses and given at 8-hour intervals. The maintenance dosage is approximately ½ of the initial dose.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Because of postmarketing reports of severe liver injury in pediatric patients treated with propylthiouracil, methimazole is the preferred choice when an antithyroid drug is required for a pediatric patient [see DOSAGE AND ADMINISTRATION].

Dosage forms

Philippines

  • Tablet: 5 mg, 10 mg, 20 mg, 30 mg

Registered products in the Philippines

20 products registered with the Food and Drug Administration (FDA) Philippines list Methimazole as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Thiamazole (10 products). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products20
Philippine FDA-registered products for Methimazole
Package insert
Levothinov 20Methimazole
20mg TabletAlu/Alu Blister Pack x 10's (Box Of 30’s and Box Of 100'S)
Rx
Ratnatris Pharmaceuticals Private LimitedIndia
Medinova Pharmaceutical Inc.
DRP-19111
Oct 28, 2031
Levothinov 5Methimazole
5mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s and 100's)
Rx
Ratnatris Pharmaceuticals Private LimitedIndia
Medinova Pharmaceutical Inc
DRP-19112
Oct 28, 2031
MethazolMethimazole
20 mg TabletAlu/White-Opaque PVC Blister Pack x 10's Box of 100's
Rx
Sydenham Laboratories, Inc.Philippines
Trader: Alternative Platform Exchange, Inc.
DR-XY35916
May 28, 2029
MethazolMethimazole
5 mg TabletWide-mouth Amber Glass Bottle x 100's Box of 1's
Rx
Sydenham Laboratories, Inc.Philippines
Trader: Alternative Platform Exchange, Inc.
DR-XY30375
Dec 7, 2029
MethimaxThiamazoleVariant spelling
5 mg TabletAlu/White Opaque PVC Blister Pack x 10’s (Box of 100’s)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Alternative Platform Exchange Inc
DRP-12832
Aug 24, 2030
MethimedMethimazole
20 mg TabletAlu/White opaque PVC Blister Pack x 10's (Box of 100's)
Rx
Life Square Laboratories Inc.Philippines
Trader: MedChoice Pharma, Inc.
DRP-10939
Dec 21, 2026
MethimedThiamazoleVariant spelling
5mg TabletAlu/White opaque PVC Blister Pack x 10's (Box of 100's)
Rx
Life Square Laboratories Inc.Philippines
Trader: MedChoice Pharma, Inc.
DRP-10940
Dec 21, 2026
Methinov-20Methimazole
20mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s)
Rx
Ratnatris Pharmaceuticals Private LimitedIndia
Medinova Pharmaceutical Inc.
DRP-18987
Oct 14, 2031
Methinov-5Methimazole
5mg TabletAlu/Alu Blister pack x 10's (Box of 30’s and 100's)
Rx
Ratnaris Pharmaceuticals Private LimitedIndia
Medinova Pharmaceutical Inc.
DRP-19059
Oct 22, 2031
NoneThiamazoleVariant spelling
5 mg TabletAlu/Red PVC Blister Pack x 10's Box of 100's
Rx
Drugmakers Laboratories, IncPhilippines
—
DRP-5504
Feb 24, 2030
StrumazolThiamazoleVariant spelling
10 mg TabletAlu/ PVC Blister Pack x 20's Box of 100's
Rx
Orifarm Manufacturing Poland Sp. zo.oPoland
Importer: Aspen Philippines, Inc.
DR-XY38132
Oct 3, 2027
StrumazolThiamazoleVariant spelling
30 mg TabletAlu/PVC Blister x 10's (Box of 30's)
Rx
Orifarm Manufacturing Poland Sp. zo.oPoland
Importer: Aspen Philippines Inc.
DR-XY25715
Feb 15, 2028
TapazoleThiamazoleVariant spelling
20 mg TabletAmber Bottle x 100’s
Rx
Interphil Laboratories, Inc.Philippines
Trader: A. Menarini Philippines, Inc.
DRP-1691
Oct 30, 2029
TapazoleThiamazoleVariant spelling
5 mg TabletAmber Bottle x 100’s
Rx
Interphil Laboratories, Inc.Philippines
Trader: A. Menarini Philippines, Inc.
DR-4441
Aug 31, 2029
TapdinMethimazole
20 mg TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 100's)
Rx
Sydenham Laboratories, Inc.Philippines
Trader: MedChoice Endocrine Group, Inc.
DRP-12826
Mar 14, 2027
TapdinMethimazole
5 mg TabletAlu/White-Opaque PVC Blister Pack x 10's (Box of 100's)
Rx
Sydenham Laboratories, Inc.Philippines
Trader: Medchoice Endocrine Group, Inc.
DRP-12823
May 28, 2029
Tapdin ®ThiamazoleVariant spelling
20 mg TabletAlu/White opaque PVC blister pack x 10's (Box of 100’s)
Rx
Lifesquare Laboratories IncPhilippines
Medchoice Endocrine Group, IncTrader: Alternative Platform Exchange Inc
DRP-10939-01
Dec 21, 2026
ThymazThiamazoleVariant spelling
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-15410
Jul 5, 2029
ThymizoleMethimazole
5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
4Care Lifesciences Pvt. Ltd.India
Aglobal Care, Inc.
DRP-16781
Jul 10, 2030
UnbrandedThiamazoleVariant spelling
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-15334
Jun 21, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS First Trimester Use of Methimazole and Congenital Malformations Methimazole crosses the placental membranes and can cause fetal harm, when administered in the first trimester of pregnancy. Rare instances of congenital defects, including aplasia cutis, craniofacial malformations (facial dysmorphism; choanal atresia), gastrointestinal malformations (esophageal atresia with or without tracheoesophageal fistula), omphalocele and abnormalities of the omphalomesenteric duct have occurred in infants born to mothers who received methimazole tablets in the first trimester of pregnancy.

If methimazole tablets are used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus. Because of the risk for congenital malformations associated with use of methimazole tablets in the first trimester of pregnancy, it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism.

If methimazole tablets are used, the lowest possible dose to control the maternal disease should be given. Agranulocytosis Agranulocytosis is potentially a life-threatening adverse reaction of methimazole therapy. Patients should be instructed to immediately report to their physicians any symptoms suggestive of agranulocytosis, such as fever or sore throat.

Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur. The drug should be discontinued in the presence of agranulocytosis or aplastic anemia (pancytopenia), and the patient’s bone marrow indices should be monitored. Liver Toxicity Although there have been reports of hepatotoxicity (including acute liver failure) associated with methimazole, the risk of hepatotoxicity appears to be less with methimazole than with propylthiouracil, especially in the pediatric population.

Symptoms suggestive of hepatic dysfunction (anorexia, pruritus, right upper quadrant pain, etc.) should prompt evaluation of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST). Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal.

Hypothyroidism Methimazole can cause hypothyroidism necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Because the drug readily crosses placental membranes, methimazole can cause fetal goiter and cretinism when administered to a pregnant woman. For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy [see PRECAUTIONS, Pregnancy].

Vasculitis Cases of vasculitis resulting in severe complications have been reported in patients receiving methimazole therapy. These cases of vasculitis include: leukocytoclastic cutaneous vasculitis, acute kidney injury and glomerulonephritis, alveolar/pulmonary hemorrhage, CNS vasculitis, and neuropathy. Most cases were associated with anti-neutrophilic cytoplasmic antibodies (ANCA)-positive vasculitis.

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. If vasculitis is suspected, discontinue therapy and initiate appropriate intervention.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Anticoagulants (oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. ß-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid.

Digitalis glycosides: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed. Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoiesis (agranulocytosis, granulocytopenia, thrombocytopenia, and aplastic anemia), drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely.

There have been postmarketing case reports of acute pancreatitis. There are reports of a vasculitis, often associated with the presence of anti-neutrophilic cytoplasmic antibodies (ANCA), resulting in severe complications [see WARNINGS]. Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.

To report SUSPECTED ADVERSE REACTIONS, contact AiPing Pharmaceutical, Inc. at 1-844-374-0016 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy [See WARNINGS.] If methimazole tablets are used during the first trimester of pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus. In pregnant women with untreated or inadequately treated Graves’ disease, there is an increased risk of adverse events of maternal heart failure, spontaneous abortion, preterm birth, stillbirth and fetal or neonatal hyperthyroidism.

Because methimazole crosses placental membranes and can induce goiter and cretinism in the developing fetus, hyperthyroidism should be closely monitored in pregnant women and treatment adjusted such that a sufficient, but not excessive, dose be given during pregnancy. In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction of dosage may be possible.

In some instances, anti-thyroid therapy can be discontinued several weeks or months before delivery. Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use an alternative anti-thyroid medication in pregnant women requiring treatment for hyperthyroidism, particularly in the first trimester of pregnancy during organogenesis.

Given the potential maternal adverse effects of propylthiouracil (e.g., hepatotoxicity), it may be preferable to switch from propylthiouracil to methimazole for the second and third trimesters.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Methimazole is present in breast milk. However, several studies found no effect on clinical status in nursing infants of mothers taking methimazole. A long-term study of 139 thyrotoxic lactating mothers and their infants failed to demonstrate toxicity in infants who are nursed by mothers receiving treatment with methimazole. Monitor thyroid function at frequent (weekly or biweekly) intervals.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Methimazole is readily absorbed in the gastrointestinal tract, metabolized in the liver, and excreted in the urine.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection. Methimazole is readily absorbed in the gastrointestinal tract, metabolized in the liver, and excreted in the urine.

Formulary and pricing (Philippines)

Formulary and coverage

Philippine National FormularyListed as Methimazole (thiamazole)
PNF listingOral: 5 mg and 10 mg tablet
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Methimazole · AiPing Pharmaceutical, Inc. [US FDA-approved label, version 2, August 20, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06bb4bcc-5e47-48b6-a76c-648f846704e8
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .